ProCE Banner Activity

Phase III KEYNOTE-789: Pemetrexed/Platinum Chemotherapy ± Pembrolizumab in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC

Conference Coverage
Slideset

Final results showed that the addition of pembrolizumab to pemetrexed/platinum chemotherapy did not significantly prolong survival in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous NSCLC.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure